Antiosteoporosis Medication Prescriptions After Fragility Fractures

William K Silverstein; Sping Wang; Mahnaz Alavinejad; Ania Sarnocinska; Nathan M Stall; Kamil Malikov; Michael P Hillmer; Jonathan S Zipursky

doi:10.1001/jamanetworkopen.2024.38393

Antiosteoporosis Medication Prescriptions After Fragility Fractures

JAMA Netw Open. 2024 Oct 1;7(10):e2438393. doi: 10.1001/jamanetworkopen.2024.38393.

Authors

William K Silverstein^{1

2

3}, Sping Wang⁴, Mahnaz Alavinejad⁴, Ania Sarnocinska⁴, Nathan M Stall^{1

5

6}, Kamil Malikov⁴, Michael P Hillmer^{3

4}, Jonathan S Zipursky^{1

2

3

7}

Affiliations

¹ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
³ Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
⁴ Ontario Ministry of Health, Toronto, Ontario, Canada.
⁵ Women's Age Lab, Women's College Hospital, Toronto, Ontario, Canada.
⁶ Division of General Internal Medicine and Geriatrics, Sinai Health System and University Health Network, Toronto, Ontario, Canada.
⁷ Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

No abstract available

Plain language summary

This cohort study assesses prescribing rates for antiosteoporosis medication following a fragility fracture and factors associated with filling a prescription after a fracture among patients in Ontario, Canada.

MeSH terms

Aged
Aged, 80 and over
Bone Density Conservation Agents* / therapeutic use
Drug Prescriptions / statistics & numerical data
Female
Humans
Male
Middle Aged
Osteoporosis / drug therapy
Osteoporotic Fractures* / drug therapy
Osteoporotic Fractures* / prevention & control

Substances

Bone Density Conservation Agents